Gilead closed a strategic collaboration with Precision BioSciences to develop therapies targeting the in vivo elimination of hepatitis B virus (HBV) using Precision’s proprietary genome editing platform, Arcus. According to the company, Precision will be primarily responsible for the development, formulation, and preclinical evaluation of the investigational nucleases, and Gilead will be responsible for the clinical development and commercialization of potential therapies. R&D activities will be funded by Gilead, while Precision is eligible to receive milestone payments up to $445 million, plus tiered royalties.

Gilead also closed a license agreement with Trianni to use its transgenic human monoclonal antibody discovery platform to support the Gilead’s drug discovery efforts.